C5補体阻害剤の世界市場レポート 2025年

C5補体阻害剤の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.2%で134億5,000万米ドルに成長します。予測期間中の成長は、医薬品メーカー間の提携、ヘルスケアインフラの進歩、高額な医療費、革新的な治療に対する需要の増加、補体介在性疾患の有病率の上昇などに起因すると考えられます。予測期間中の主な動向としては、バイオテクノロジーの進歩、RNAベースの手法や遺伝子治療への投資の拡大、診断ツールの改善、新規治療法の出現、モノクローナル抗体療法の開発などが挙げられます。

慢性疾患の有病率の増加は、C5補体阻害剤市場の成長を大きく促進すると予想されます。慢性疾患は、進行が緩やかで、合併症を予防するために継続的な管理を必要とすることが多い長期的な病状です。慢性疾患の増加は、食生活の乱れ、運動不足、喫煙、ストレスなどのライフスタイル要因によるところが大きく、これらが長期的な健康悪化の原因となっています。C5補体阻害剤は、発作性夜間ヘモグロビン尿症（PNH）、非定型溶血性尿毒症症候群（aHUS）、その他の補体介在性疾患などの疾患において、補体系の過剰活性化を阻害し、炎症を抑え、組織損傷を予防し、疾患の転帰を改善することにより、慢性疾患の治療に重要な役割を果たしています。例えば、2022年10月、世界心臓連盟は、心血管疾患関連の死亡者数が2030年の約2,220万人から2050年には3,230万人に増加すると予測されると報告し、慢性疾患の負担が増大していることを強調しました。このような慢性疾患の有病率の上昇は、C5補体阻害剤市場拡大の主要な促進要因です。

C5補体阻害剤市場の各社は、重症筋無力症などの患者により便利で効果的な選択肢を提供するため、自己投与型C5阻害薬などの革新的治療の開発に注力しています。自己投与型C5阻害剤は患者用に設計されており、補体C5タンパク質を標的としてブロックすることにより、炎症や免疫介在性障害を軽減します。注目すべき例としては、2023年10月に米国食品医薬品局（FDA）から承認されたジルブライスク（ジルコプラン）があります。ユニオン・キミク・ベルジュ（UCB）SAが開発したこの1日1回皮下投与のC5補体阻害薬は、抗アセチルコリン受容体（AChR）抗体陽性の全身型重症筋無力症の成人に新たな治療選択肢を提供します。ジルブリスクの承認により、UCB社の神経領域におけるポートフォリオが強化され、自己免疫性神経筋疾患に苦しむ患者さんの治療選択肢が広がり、治療の利便性が向上します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のC5補体阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のC5補体阻害剤市場：成長率分析
• 世界のC5補体阻害剤市場の実績：規模と成長, 2019-2024
• 世界のC5補体阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界のC5補体阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のC5補体阻害剤市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 長時間作用型C5阻害剤
• 短時間作用型C5阻害剤
• 世界のC5補体阻害剤市場：薬剤別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エクリズマブ
• ラブリズマブ
• その他の薬剤
• 世界のC5補体阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• 経口
• 世界のC5補体阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のC5補体阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 発作性夜間ヘモグロビン尿症
• 非典型溶血性尿毒症症候群
• 全身性重症筋無力症
• 視神経脊髄炎スペクトラム障害
• その他の用途
• 世界のC5補体阻害剤市場、長時間作用型C5阻害剤、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• クロバリマブ
• ポゼリマブ
• テシドルマブ
• その他の長時間作用型C5阻害剤
• 世界のC5補体阻害剤市場、短時間作用型C5阻害剤、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジルコプラン
• セムジシラン
• ノマコパン
• その他の短時間作用型C5阻害剤

第7章 地域別・国別分析

• 世界のC5補体阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のC5補体阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• C5補体阻害剤市場：競合情勢
• C5補体阻害剤市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co. Ltd.
• UCB Pharma SA
• Swedish Orphan Biovitrum AB（Sobi）
• Alnylam Pharmaceuticals Inc.
• BioCryst Pharmaceuticals Inc.
• Apellis Pharmaceuticals Inc.
• Omeros Corporation
• Dianthus Therapeutics Inc.
• Kira Pharmaceuticals
• Biopharma PEG Scientific Inc.
• ProbeChem Biochemicals
• InflaRx NV
• Akari Therapeutics Plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• C5補体阻害剤市場2029：新たな機会を提供する国
• C5補体阻害剤市場2029：新たな機会を提供するセグメント
• C5補体阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

C5 complement inhibitors are a class of targeted immunomodulatory biologic agents that specifically block the cleavage of complement component 5 (C5) into its active fragments, C5a and C5b. By doing so, they prevent the formation of the membrane attack complex (MAC) and mitigate the downstream inflammatory and cytolytic processes linked to the overactivation of the complement system. These inhibitors are used to treat complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and certain forms of generalized myasthenia gravis, where excessive complement activity contributes to disease pathology.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main products in C5 complement inhibitors are long-acting C5 inhibitors and short-acting C5 inhibitors. Long-acting C5 complement inhibitors are therapeutic agents designed to provide prolonged suppression of C5 activity, thereby reducing the frequency of administration while maintaining effective control over immune-mediated conditions. The drugs included in this category are eculizumab, ravulizumab, and others, which can be administered via intravenous, subcutaneous, or oral routes. These inhibitors are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, with applications in conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, and others.

The C5 complement inhibitors market research report is one of a series of new reports from The Business Research Company that provides C5 complement inhibitors market statistics, including C5 complement inhibitors industry global market size, regional shares, competitors with a C5 complement inhibitors market share, detailed C5 complement inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the C5 complement inhibitors industry. This C5 complement inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The C5 complement inhibitors market size has grown rapidly in recent years. It will grow from$6.91 billion in 2024 to $7.91 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth during the historic period can be attributed to the rising prevalence of rare and chronic diseases, the growing demand for targeted therapies, increased awareness among healthcare providers, higher investments in research and development, and favorable reimbursement policies.

The C5 complement inhibitors market size is expected to see rapid growth in the next few years. It will grow to$13.45 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth during the forecast period can be attributed to collaborations between drug manufacturers, advancements in healthcare infrastructure, high healthcare expenditure, increasing demand for innovative treatments, and the rising prevalence of complement-mediated illnesses. Key trends during the forecast period include advancements in biotechnology, growing investment in RNA-based methods and gene therapy, improvements in diagnostic tools, the emergence of novel therapies, and developments in monoclonal antibody therapies.

The increasing prevalence of chronic diseases is expected to significantly propel the growth of the C5 complement inhibitors market. Chronic diseases are long-term medical conditions that progress slowly and often require continuous management to prevent complications. The rise in chronic diseases is largely driven by lifestyle factors such as poor diet, physical inactivity, smoking, and stress, which contribute to long-term health deterioration. C5 complement inhibitors play a key role in treating chronic diseases by blocking the overactivation of the complement system, reducing inflammation, preventing tissue damage, and improving disease outcomes in conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other complement-mediated disorders. For example, in October 2022, the World Heart Federation reported that cardiovascular disease-related deaths are projected to rise from around 22.2 million by 2030 to 32.3 million by 2050, highlighting the growing burden of chronic diseases. This rising prevalence of chronic diseases is a major driver for the expansion of the C5 complement inhibitors market.

Companies in the C5 complement inhibitors market are focusing on developing innovative treatments, such as self-administered C5 inhibitors, to provide more convenient and effective options for patients with generalized myasthenia gravis and other conditions. Self-administered C5 inhibitors are designed for patient use and work by targeting and blocking the complement C5 protein, reducing inflammation and immune-mediated damage. A notable example is the approval of Zilbrysq (zilucoplan) by the U.S. Food and Drug Administration (FDA) in October 2023. This once-daily subcutaneous C5 complement inhibitor, developed by Union Chimique Belge (UCB) SA, provides a new treatment option for adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody-positive. The approval of Zilbrysq strengthens UCB's neurology portfolio, expanding treatment choices for individuals suffering from autoimmune neuromuscular disorders and improving the convenience of treatment.

In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired Iveric Bio Inc. for $5.9 billion to enhance its ophthalmology pipeline and strengthen its presence in the retinal disease market. This acquisition grants Astellas access to Iveric Bio's lead asset, Zimura, a complement C5 inhibitor designed to treat geographic atrophy secondary to age-related macular degeneration (AMD). Iveric Bio, a US-based biopharmaceutical company, is developing novel treatments in the complement C5 inhibitor space. The acquisition positions Astellas to further expand its offerings in retinal diseases, potentially improving patient outcomes for those suffering from vision loss associated with complement-mediated conditions.

Major players in the c5 complement inhibitors market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis AG, Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., UCB Pharma SA, Swedish Orphan Biovitrum AB(Sobi), Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, Dianthus Therapeutics Inc., Kira Pharmaceuticals, Biopharma PEG Scientific Inc., ProbeChem Biochemicals, InflaRx NV, Akari Therapeutics Plc

North America was the largest region in the C5 complement inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the C5 Complement Inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The C5 complement inhibitors market consists of sales of zilucoplan, cemdisiran, tesidolumab, and biologics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

C5 Complement Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on c5 complement inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for c5 complement inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The c5 complement inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Long Acting C5 Inhibitors; Short Acting C5 Inhibitors
• 2) By Drug: Eculizumab; Ravulizumab; Other Drugs
• 3) By Route Of Administration: Intravenous; Subcutaneous; Oral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By Application: Paroxysmal Noctural Hemoglobuinuria; Atyptical Hemolytic Uremic Syndrome; Generalized Myasthenia Gravis; Neuromyelitis Optics Spectrum Disorder; Other Applications
• Subsegments:
• 1) By Long Acting C5 Inhibitors: Crovalimab; Pozelimab; Tesidolumab; Other Long-Acting C5 Inhibitors
• 2) By Short Acting C5 Inhibitors: Zilucoplan; Cemdisiran; Nomacopan; Other Short-Acting C5 Inhibitors
• Companies Mentioned: F. Hoffmann-La Roche AG; AstraZeneca plc; Novartis AG; Amgen Inc.; Merck KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. C5 Complement Inhibitors Market Characteristics

3. C5 Complement Inhibitors Market Trends And Strategies

4. C5 Complement Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global C5 Complement Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global C5 Complement Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global C5 Complement Inhibitors Market Growth Rate Analysis
• 5.4. Global C5 Complement Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global C5 Complement Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global C5 Complement Inhibitors Total Addressable Market (TAM)

6. C5 Complement Inhibitors Market Segmentation

• 6.1. Global C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long Acting C5 Inhibitors
• Short Acting C5 Inhibitors
• 6.2. Global C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eculizumab
• Ravulizumab
• Other Drugs
• 6.3. Global C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.4. Global C5 Complement Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global C5 Complement Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Paroxysmal Nocturnal Hemoglobinuria
• Atypical Hemolytic Uremic Syndrome
• Generalized Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder
• Other Applications
• 6.6. Global C5 Complement Inhibitors Market, Sub-Segmentation Of Long Acting C5 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Crovalimab
• Pozelimab
• Tesidolumab
• Other Long-Acting C5 Inhibitors
• 6.7. Global C5 Complement Inhibitors Market, Sub-Segmentation Of Short Acting C5 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zilucoplan
• Cemdisiran
• Nomacopan
• Other Short-Acting C5 Inhibitors

7. C5 Complement Inhibitors Market Regional And Country Analysis

• 7.1. Global C5 Complement Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global C5 Complement Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific C5 Complement Inhibitors Market

• 8.1. Asia-Pacific C5 Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China C5 Complement Inhibitors Market

• 9.1. China C5 Complement Inhibitors Market Overview
• 9.2. China C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India C5 Complement Inhibitors Market

• 10.1. India C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan C5 Complement Inhibitors Market

• 11.1. Japan C5 Complement Inhibitors Market Overview
• 11.2. Japan C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia C5 Complement Inhibitors Market

• 12.1. Australia C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia C5 Complement Inhibitors Market

• 13.1. Indonesia C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea C5 Complement Inhibitors Market

• 14.1. South Korea C5 Complement Inhibitors Market Overview
• 14.2. South Korea C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe C5 Complement Inhibitors Market

• 15.1. Western Europe C5 Complement Inhibitors Market Overview
• 15.2. Western Europe C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK C5 Complement Inhibitors Market

• 16.1. UK C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany C5 Complement Inhibitors Market

• 17.1. Germany C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France C5 Complement Inhibitors Market

• 18.1. France C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy C5 Complement Inhibitors Market

• 19.1. Italy C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain C5 Complement Inhibitors Market

• 20.1. Spain C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe C5 Complement Inhibitors Market

• 21.1. Eastern Europe C5 Complement Inhibitors Market Overview
• 21.2. Eastern Europe C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia C5 Complement Inhibitors Market

• 22.1. Russia C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America C5 Complement Inhibitors Market

• 23.1. North America C5 Complement Inhibitors Market Overview
• 23.2. North America C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA C5 Complement Inhibitors Market

• 24.1. USA C5 Complement Inhibitors Market Overview
• 24.2. USA C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada C5 Complement Inhibitors Market

• 25.1. Canada C5 Complement Inhibitors Market Overview
• 25.2. Canada C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America C5 Complement Inhibitors Market

• 26.1. South America C5 Complement Inhibitors Market Overview
• 26.2. South America C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil C5 Complement Inhibitors Market

• 27.1. Brazil C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East C5 Complement Inhibitors Market

• 28.1. Middle East C5 Complement Inhibitors Market Overview
• 28.2. Middle East C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa C5 Complement Inhibitors Market

• 29.1. Africa C5 Complement Inhibitors Market Overview
• 29.2. Africa C5 Complement Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa C5 Complement Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa C5 Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. C5 Complement Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. C5 Complement Inhibitors Market Competitive Landscape
• 30.2. C5 Complement Inhibitors Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

31. C5 Complement Inhibitors Market Other Major And Innovative Companies

• 31.1. Regeneron Pharmaceuticals Inc.
• 31.2. Astellas Pharma Inc.
• 31.3. Chugai Pharmaceutical Co. Ltd.
• 31.4. UCB Pharma SA
• 31.5. Swedish Orphan Biovitrum AB(Sobi)
• 31.6. Alnylam Pharmaceuticals Inc.
• 31.7. BioCryst Pharmaceuticals Inc.
• 31.8. Apellis Pharmaceuticals Inc.
• 31.9. Omeros Corporation
• 31.10. Dianthus Therapeutics Inc.
• 31.11. Kira Pharmaceuticals
• 31.12. Biopharma PEG Scientific Inc.
• 31.13. ProbeChem Biochemicals
• 31.14. InflaRx NV
• 31.15. Akari Therapeutics Plc

32. Global C5 Complement Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The C5 Complement Inhibitors Market

34. Recent Developments In The C5 Complement Inhibitors Market

35. C5 Complement Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 C5 Complement Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 C5 Complement Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 C5 Complement Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34786_C5_Complement_Inhibitors_GMR_2025